Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.67 |
| ▸ | DRD3 | P35462 | 10/20 | 0.67 |
| ▸ | HTR2A | P28223 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486488 | 1.00 | DRD2 (0.67) | DRD2DRD3HTR2AKDM4EALDH1A1 | |
| SCHEMBL4496109 | 0.93 | DRD2 (0.65) | DRD2DRD3HTR2AKDM4EALDH1A1 | |
| SCHEMBL13629882 | 0.93 | DRD2 (0.65) | DRD2DRD3HTR2AKDM4EALDH1A1 | |
| SCHEMBL13630125 | 0.91 | DRD2 (0.66) | DRD2DRD3HTR2AKDM4EALDH1A1 | |
| SCHEMBL4483665 | 0.91 | DRD2 (0.66) | DRD2DRD3HTR2AKDM4EALDH1A1 | |
| SCHEMBL13637955 | 0.90 | DRD2 (0.72) | DRD2DRD3KDM4EALDH1A1LMNA | |
| SCHEMBL4502953 | 0.89 | DRD2 (0.63) | DRD2DRD3HTR2AKDM4EALDH1A1 | |
| SCHEMBL14346819 | 0.89 | DRD3 (0.61) | DRD2DRD3HTR2A | |
| SCHEMBL13630254 | 0.89 | DRD3 (0.61) | DRD2DRD3HTR2A | |
| SCHEMBL4482269 | 0.89 | DRD3 (0.61) | DRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885DRD3 1/4885HTR2A 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.